论文信息 - Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three‐year results from the UNCOVER‐3 study - 字舞流文

Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three‐year results from the UNCOVER‐3 study

S. Ball | L. Puig | C. Leonardi | L. Mallbris | S. Philipp | Lu Zhang | P. Fernández-Peñas | C. Maari | O. Goldblum | N. Burkhardt | Pablo Gonzalez

[1] L. Iversen,et al. Efficacy and safety of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER‐3) , 2017, Journal of the American Academy of Dermatology.

[2] K. Reich,et al. Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results. , 2017, Journal of Drugs in Dermatology.

[3] J. Erickson,et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[4] M. Lebwohl,et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.

[5] Sarah L. Gaffen,et al. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing , 2014, Nature Reviews Immunology.